

1 TROUTMAN PEPPER
HAMILTON SANDERS LLP
2 Ben Lewis Wagner,* Bar No. 243594
ben.wagner@troutman.com
3 Christopher Franich, Bar No. 285720
chris.franich@troutman.com
4 11682 El Camino Real, Suite 400
San Diego, CA 92130-2092
5 Telephone: 858.509.6000
Facsimile: 858.509.6040
6 *Lead Counsel

7 TROUTMAN PEPPER
HAMILTON SANDERS LLP
8 *Pro hac vice forthcoming*
Robert Schaffer, NY Bar No. 1968445
9 robert.schaffer@troutman.com
875 Third Avenue
10 New York, NY 10022
Telephone: 212.704.6000
11 Facsimile: 212.704.6288

12 Attorneys for Plaintiff
Allele Biotechnology and Pharmaceuticals, Inc.

13 UNITED STATES DISTRICT COURT
14 SOUTHERN DISTRICT OF CALIFORNIA

15
16 Allele Biotechnology and
Pharmaceuticals, Inc., a California
17 corporation

18 Plaintiff,

19 v.

20 Pfizer, Inc., a Delaware corporation;
BioNTech SE, a German company;
21 BioNTech US, Inc., a Delaware
corporation; and DOES 1-30

22 Defendants.

Case No. **'20CV1958 GPC AHG**

**COMPLAINT FOR PATENT
INFRINGEMENT**

JURY TRIAL DEMAND

23
24 Plaintiff Allele Biotechnology and Pharmaceuticals, Inc. (hereafter “Allele”)
25 brings this Complaint for monetary and declaratory relief against Defendants Pfizer,
26 Inc., a Delaware corporation (“Pfizer”), BioNTech SE, a German company, and
27 BioNTech US, Inc., a Delaware company (collectively “BioNTech”) (and each
28

1 Defendant collectively “Defendants”) to address Defendants’ infringement of
2 Allele’s patent related to Defendants’ COVID-19 vaccine, BNT162.

3 1. This action arises under the patent laws of the United States, 35 U.S.C.
4 § 1 *et seq.*, based on Defendants’ infringement of United States Patent No.
5 10,221,221 (“the ‘221 Patent”).

6 INTRODUCTION

7 2. Prior to the current COVID-19 crisis, Allele had already developed the
8 revolutionary mNeonGreen. mNeonGreen belongs to Allele, as does the ’221 Patent
9 covering the exclusive right to use mNeonGreen. mNeonGreen is an artificial
10 fluorescent that Allele painstakingly developed over many years through the genius
11 of its inventors. It is the world’s brightest monomeric fluorescent protein, dubbed by
12 third party industry veterans as the “King of fluorescent proteins.” A prominent
13 university used mNeonGreen to make the “gold standard” COVID-19 assay for
14 effectively testing against vaccine candidates, which Pfizer and BioNTech readily
15 took for their own unauthorized commercial testing and development.

16 3. The results included selection of their BNT162 MRNA-based COVID-
17 19 vaccine candidate currently in a Phase 3 trial. What’s more, mNeonGreen has
18 been used throughout Defendants’ COVID-19 vaccine trials, right up to the present.
19 Only through use of mNeonGreen were Defendants able to develop and test the
20 BNT162 vaccine candidate at lightspeed making them first to market, earning them
21 an immediate \$445 million in grants and over \$4 billion in sales of the vaccine to-
22 date. All of this was simply the downstream benefit that Defendants enjoyed (and
23 presumably the world will enjoy from the vaccine) from their choice to use Allele’s
24 mNeonGreen.

25 4. Allele’s breakthrough in fluorescent protein technology is
26 mNeonGreen, the latest in its history of innovation. Since 1999, Allele has been a
27 leader in developing technology and research tools for clinical and therapeutic uses.
28 Among other achievements, Allele’s advancements have been directed to RNA

1 interference, Fluorescent Proteins, Induced Pluripotent Stem Cells (iPSCs), Genome
2 Editing, and camelid derived Single Domain Antibodies. More recently since
3 January of 2020, Allele has been actively engaged in combating COVID-19,
4 initiating impactful diagnostic and therapeutic platforms premised on speed,
5 accuracy, and sensitivity.

6 5. This lawsuit follows because Defendants made the deliberate and
7 calculated decision to infringe, rather than even so much as pick up the phone and
8 seek to obtain the rights to use Allele’s valuable intellectual property.

9 **JURISDICTION AND VENUE**

10 6. This is an action for patent infringement arising under the patent laws
11 of the United States, 35 U.S.C. § 271.

12 7. This Court has subject matter jurisdiction over this action under 28
13 U.S.C. §§ 1331, 1332 and 1338(a).

14 8. This Court has personal jurisdiction over Defendants because
15 Defendants regularly conduct business within, and specifically direct their business
16 activities to, the State of California and the Southern District of California (“this
17 District”). Defendants have purposefully availed themselves of the opportunity to
18 conduct business in this state through systematic and continuous dealings in this state.
19 Defendants’ actions that give rise to personal jurisdiction include, but are not limited
20 to the following: making and using infringing products in this State and in this
21 District, knowing and intending that the infringing products would be used in this
22 District, deriving substantial revenue from the use of infringing products within this
23 District, and expecting their infringing actions to have consequences in this District.

24 9. Venue is proper as to BioNTech SE in this judicial district pursuant to,
25 *inter alia*, 28 U.S.C. § 1391(c)(3).

26 10. Venue also is proper as to Defendants under 28 U.S.C. § 1400(b). Each
27 Defendant has committed, induced others to commit, or contributed to others
28 committing, acts of infringement in this District, including by conducting an

1 international trial of the vaccine utilizing mNeonGreen with over 30,000 participants
2 and study sites including in [San Diego County](#), Clinical Study Identifier
3 [NCT04368728](#). [Pfizer](#) has a regular and established place of business in La Jolla,
4 California which on information and belief is a 25-acre campus with over half a
5 million square feet of buildings and “one of the largest concentrations of academic
6 and biotechnology institutions in the world.” [BioNTech](#) has a regular and established
7 place of business at 11535 Sorrento Valley Rd #400, San Diego CA, namely its
8 15,000 square foot US [laboratory](#), research and development [facility](#), which [it](#)
9 [identified](#) as of January 2020 as its U.S. research and development hub.

10 **THE PARTIES**

11 11. Allele is a California corporation with its principal place of business
12 being, 6404 Nancy Ridge Drive, San Diego, California 92121.

13 12. Allele was founded in 1999 and is recognized as a leading developer of
14 technology for clinical and therapeutic use, such as research tools for drug candidates
15 in vaccine trials as in the current race for the cure to COVID-19.

16 13. Defendant Pfizer is a company organized and existing under the laws of
17 the State of Delaware with its principal place of business at 235 East 42nd Street,
18 New York, NY 10017.

19 14. Defendant BioNTech SE, is a company organized and existing under
20 the laws of Germany, traded in the United States on NASDAQ, with its principal
21 place of business located in An der Goldgrube 12 Mainz, 55131 Germany. Defendant
22 BioNTech US, Inc. is a company organized and existing under the laws of the State
23 of Delaware with on information and belief its principal place of business located in
24 Cambridge, Massachusetts.

25 15. The true names and capacities, whether individual, corporate, associate,
26 or otherwise, of defendants DOES 1 through 30, inclusive, are unknown to Allele,
27 who therefore sues said defendants by such fictitious names. Allele will amend this
28 Complaint to state their true names and capacities when the same is ascertained.

1 Allele is informed and believes that at all times herein mentioned, each defendant
2 named herein was the agent of each of the remaining defendants and, in doing the
3 things herein alleged, was acting within the course and scope of said agency. Any
4 reference in this Complaint to the actions or inactions of any defendant, whether such
5 reference is made to such defendant by specific name or otherwise, is also a reference
6 to the actions or inactions of DOES 1 through 30, inclusive.

7 16. Defendant Pfizer is, among other things, engaged with BioNTech in the
8 development of their BNT162 mRNA-based vaccine candidate, which was
9 developed using Allele's mNeonGreen. The vaccine candidate is currently part of
10 an ongoing Phase 3 trial that, on information and belief, has already surpassed
11 enrollment of 30,000 participants as of September 2020. Based on promising results
12 (premised on Defendants' use of mNeonGreen, which itself does not require
13 government approval for clinical use), the U.S. government and U.S. Department of
14 Health and Human Services have ordered up to 600,000,000 doses of their vaccine
15 candidate.

16 17. At all times mentioned herein, defendants, and each of them, were the
17 agents, servants, co-conspirators, or employees of one another, and the acts and
18 omissions herein alleged were done or suffered by them, acting individually and
19 through or by their alleged capacity, within the scope of their authority. Each of the
20 defendants aided and abetted and rendered substantial assistance in the
21 accomplishment of the acts complained of herein. In taking the actions, as
22 particularized herein, to aid and abet and substantially assist in the commission of the
23 misconduct complained of, each defendant acted with an awareness of his, her or its
24 primary wrongdoing and realized that his, her or its conduct would substantially
25 assist in the accomplishment of that misconduct and was aware of his, her or its
26 overall contribution to, and furtherance of the conspiracy, common enterprise, and
27 common course of conduct. Defendants' acts of aiding and abetting included, inter
28 alia, all of the acts each defendant is alleged to have committed in furtherance of the

1 conspiracy, common enterprise, and common course of conduct complained of
2 herein.

3 **FACTS**

4 **Background**

5 18. Messrs. Nathan C. Shaner, Gerard G. Lambert, Yuhui Ni, and Jiwu
6 Wang are joint inventors (collectively “Inventors”) of the ’221 Patent, entitled
7 “Monomeric yellow-green fluorescent protein from cephalochordate” and which
8 issued on March 5, 2019. A true and correct copy of the ’221 Patent is attached
9 hereto as Exhibit 1.

10 19. Although the invention(s) set forth in the ’221 Patent are best described
11 by its claims, the ’221 Patent is generally directed to isolated nucleic acid sequences
12 encoding a monomeric green/yellow fluorescent proteins, and fragments and
13 derivatives thereof.

14 20. On April 28, 2014, the Inventors assigned the yet-to-be-issued ’221
15 Patent to Allele. A true and correct copy of the assignment is attached hereto as
16 Exhibit 2.

17 21. The claims of the ’221 Patent encompass Allele’s mNeonGreen product,
18 which is a fluorescent protein used as a biological tag in genetic engineering work.
19 mNeonGreen is a monomeric protein that was derived from a tetrameric wild-type
20 yellow-green fluorescent protein isolated from the cephalochordate *Branchiostoma*
21 *lanceolatum* (a “lanYFP”). In nature, two lanYFP monomers form a dimer and two
22 dimers form an “obligate” (mandatory) tetramer. When exposed to certain
23 wavelengths of light, the lanYFP tetramer will brightly fluoresce. However, the
24 tetramer is large and often unsuitable as a fluorescent tag. The engineered
25 mNeonGreen monomer is among the brightest and most stable monomeric
26 fluorescent reporter proteins currently known.

27 22. The resulting mNeonGreen, synthetic lanYFP fluorescent protein
28 described and claimed in the ’221 Patent is widely recognized as a breakthrough, is

1 used throughout the industry, and has been called the “King of fluorescent proteins”
2 by Professor Amy Palmer, at the University of Colorado Boulder. Applications
3 involving infectious viruses, such as COVID-19 vaccine work, are high
4 concentration environments perfectly suited for mNeonGreen, as broadly recognized.
5 *See, Xie, et al, Cell Host & Microbe 27, 841-848 (May 13, 2020) and Muruato, et al.,*
6 *bioRxiv preprint: <https://doi.org/10.1101/2020.05.21.109546> (May 22, 2020), true*
7 *and correct copies of each attached hereto as Exhibit 3 (hereafter “Cell Host Article”)*
8 *and Exhibit 4, respectively.*

9 23. The commercial protein of mNeonGreen corresponds to SEQ ID NO:1
10 of the patent (claims 1, 3, 4 and 5). Allele used the nucleic acid of SEQ ID NO:2
11 (claim 3) to express this protein.

12 24. In practice, mNeonGreen facilitates quick, targeted, and precise receptor
13 research, including for potential therapeutics to treat COVID-19. The fluorescent-
14 tagged therapeutic proteins associated with mNeonGreen are constructed to
15 determine receptor expression and dynamics with therapeutic outcome for high-
16 throughput systems, as in the present global race for a vaccine to COVID-19. A key
17 hurdle in developing a vaccine for infectious diseases, such as the novel coronavirus
18 of COVID-19, is determining therapeutic outcome of potential drug candidates,
19 something which mNeonGreen readily solves.

20 25. Where there is a race against time, weaker fluorescent alternatives are
21 simply no option. mNeonGreen was the critical link in Defendants’ COVID-19
22 vaccine development and its continued trial success. This research tool is even more
23 critical in a global pandemic where the need for a vaccine to save lives has never
24 been more crucial. While Defendants were required to obtain a commercial license
25 from Allele, Defendants never sought a license with Allele or even contacted them.

26
27
28

Accused Products

26. BioNTech adopted the technology protected by the ‘221 Patent in its COVID-19 vaccine trial. *See*, SEC Form 6K, a true and correct copy attached hereto as Exhibit 5.

27. At page 21 of Form 6K shown in Exhibit 5 Page 73, BioNTech states, “[t]he SARS-CoV-2 neutralization assay used a previously described strain of SARS-CoV-2 (USA_WA1/2020) that had been rescued by reverse genetics and engineered by the **insertion of an mNeonGreen (mNG) gene** into open reading frame 7 of the viral genome.” Stated differently, the COVID-19 vaccine of Defendants’ COVID-19 vaccine trial was developed by Defendants using a DNA construct with a monomeric mNeonGreen protein inserted into the recombinant and infectious SARS-COV2-19 virus.

28. Form 6K includes a copy of Mulligan et al., Phase 1/2 Study to Describe the Safety and Immunogenicity of a COVID-19 RNA Vaccine Candidate (BNT162b1) in Adults 18 to 55 Years of Age: Interim Report (“Mulligan”), a medRxiv preprint made available on July 1, 2020 at <https://doi.org/10.1101/2020.06.30.20142570>.

29. Mulligan contains additional information about BioNTech’s work. *See* Exhibit 5 Page 62 (Exhibit 99.2, Mulligan p.1). For example, Mulligan reported dose-dependent titers of neutralizing antibodies in human subjects with safe (mild to moderate) adverse reactions:

The SARS-CoV-2 neutralization assay used a previously described strain of SARS-CoV-2 (USA_WA1/2020) that had been rescued by reverse genetics and engineered by the **insertion of an mNeonGreen (mNG) gene** into open reading frame 7 of the viral genome.[20] This reporter virus generates similar plaque morphologies and indistinguishable growth curves from wild-type virus. Viral master stocks used for the neutralization assay were grown in Vero E6 cells as previously described.[20]

Exhibit 5 Page 73 (at Exhibit 99.2, page 12).

1 30. In other words, BioNTech admits in Exhibit 5 that it used (and continues
2 using in its trials) the DNA construct described in the Cell Host Article to develop
3 and test its SARS-CoV2 vaccine.

4 31. Defendants have used and continue using the infringing DNA construct
5 described in the Cell Host Article.

6 32. In addition, scientists from the University of Texas Medical Branch
7 (UTMB), who provides the DNA construct to Defendants, reported an “urgently
8 needed ... fluorescent-based SARS-CoV-2 neutralization assay” with “gold standard”
9 results. *See* Exhibit 4 Page 40). The assay of Exhibit 4 “was built on a stable
10 mNeonGreen SARS-CoV-2” reporter virus (*Id.*, at 41) (citing the Cell Host Article)
11 and is “superior ... because it measures functional SARSCoV-2 neutralizing activity.
12 Notably, the mNeonGreen reporter assay offers a rapid, high throughput platform to
13 test COVID-19 patient sera not previously available.” *Id.*, at 43-44.

14 33. Defendants have used and continue using this infringing assay.

15 34. The Cell Host Article also evidences that UTMB made a “reverse
16 genetics system” for SARS-CoV2 by assembling seven cDNA fragments into a full-
17 genome cDNA of the virus. Three silent mutations were made to the genome as
18 biological markers (A7486T, T7489A, and T18060C), to distinguish the recombinant
19 virus from wild-type SARS-CoV2. *See* Cell Host Article at Exhibit 3 at 29, 31 (842,
20 Fig. 2E). RNA transcribed from this cDNA produced a highly infectious virus that,
21 according to UTMB, “recapitulates the replication kinetics of the original clinical
22 isolate.” *Id.*, at 29.

23 35. mNeonGreen was incorporated into this cDNA to make a reporter virus:

24 **We generated a stable mNeonGreen SARS-CoV-2**
25 **(icSARS-CoV-2-mNG)** by introducing this reporter gene
26 into ORF7 of the viral genome. icSARS-CoV-2-mNG
27 was successfully used to evaluate the antiviral activities of
28 interferon (IFN). Collectively, the reverse genetic system
 and reporter virus provide key reagents to study SARS-
 CoV-2 and develop countermeasures.

1 Cell Host Article at Exhibit 3 at 28 (841 (Summary)), Exhibit 3 at 30, 32 (843, Fig.
2 3A).

3 36. The “countermeasures” referenced in the Cell Host Article by UTMB
4 include “generation of live-attenuated vaccine candidates to respond to emerging
5 virus outbreaks”, including “**mNeonGreen virus [] be[ing] reliably used** to study
6 viral replication and pathogenesis as well as to develop vaccines and antiviral drugs.”
7 *Id.* at 29, 30.

8 37. The Key Resources Table of the Cell Host Article lists “**synthesized**
9 **mNeonGreen gene (sequence optimized)**” and refers to a publication from 2013 by
10 the Inventors which corresponds to the ’221 Patent. See, Cell Host Article at e1, e2.

11 38. mNeonGreen in UTMB’s construct is identical to SEQ ID NO:1 of the
12 ‘221 patent.

13 39. Mulligan of Exhibit 5 also states, “BioNTech is the Sponsor of the
14 study” and that “Pfizer was responsible for the design, data collection, data analysis,
15 data interpretation, and writing of the report,” confirming Defendants’ intimate
16 involvement in every aspect of the study. See Exhibits 6, 7, and 8 with true and
17 correct copies of each attached hereto which confirm mNeonGreen’s continued use
18 by Defendants in their development of a COVID-19 vaccine. Defendants directly
19 used the invention patented in the ’221 Patent, and for which Defendants have since
20 obtained hefty government grants and sales. Exhibit 5 Page 66 (at Exhibit 99.2 p. 5).

21 40. A protein made using the DNA construct used by Defendants has “at
22 least one” of the mutations in claim 1, at least three of the mutations in claim 4, at
23 least 95% sequence identity according to claims 1, 2, and 4; has at least 97% sequence
24 identity according to claim 5, and has a monomer according to claim 2.

25 41. Therefore, the mNeonGreen protein used by Defendants throughout
26 their COVID-19 vaccine trial literally infringes at least claims 1, 2, 4 and 5 of the
27 ‘221 Patent.

28

1 42. At no time has Allele granted Defendants authorization, license, or
2 permission to practice the inventions claimed in the '221 Patent.

3 43. Because of this continued infringement, Defendants were able to
4 identify their COVID-19 vaccine candidate, BNT162, as the most promising
5 candidate to commercialize.

6 **Defendants' Willful Infringement**

7 44. The '221 Patent was issued by the United States Patent and Trademark
8 Office. As an issued patent, the '221 Patent has a presumption of validity per 35
9 U.S.C. § 282.

10 45. At least claims 1, 2, 4 and 5 of the '221 Patent have all of their
11 limitations met by the Accused Product, which thus infringes the '221 Patent.

12 46. Since at least as early as May 2020, Defendants have been aware of the
13 '221 Patent, and have had actual knowledge of the '221 Patent and the obvious risk
14 of infringement by continued use of mNeonGreen throughout their development of
15 their COVID-19 vaccine candidate in the United States.

16 47. Despite their knowledge of the obvious risk of infringement of the '221
17 Patent, Defendants since at least as early as May of 2020 continued using Allele's
18 mNeonGreen throughout their ongoing COVID-19 trial.

19 48. Defendants' continued infringement was and is subjectively reckless
20 and intentional. Defendants have infringed the '221 Patent in a willful and egregious
21 manner, in wanton disregard of the '221 Patent.

22 **FIRST CLAIM FOR RELIEF**

23 (Infringement of the '221 Patent Against All Defendants)

24 49. Allele realleges and incorporates by reference all paragraphs in this
25 Complaint above as if fully set forth herein.

26 50. This is a claim for patent infringement and arises under the Patent Laws
27 of the United States and, in particular, under 35 U.S.C. §§ 271, *et seq.*
28

1 51. Defendants have in the past infringed and continue to infringe the '221
2 Patent in violation of 35 U.S.C. § 271(a) by making, using, offering to sell, and/or
3 selling, in the United States, or importing into the United States, mNeonGreen with
4 its SARS-CoV-2 neutralization assay and DNA construct that infringes at least
5 claims 1, 2, 4, and 5, of the '221 Patent.

6 52. Allele is informed and believes that Defendants have infringed, and
7 continue to infringe, the '221 patent by making, using, selling, offering for sale and/or
8 licensing products covered by at least claims 1, 2, 4, and 5 of the '221 Patent without
9 Allele's authorization or consent.

10 53. Defendants have in the past infringed and continue to infringe the '221
11 Patent in violation of 35 U.S.C. § 271(f) because Defendants supply or cause to be
12 supplied from the United States all or a substantial portion of the patented invention
13 for combination outside the United States, including use of mNeonGreen with its
14 SARS-CoV-2 neutralization assay and DNA construct throughout their COVID-19
15 vaccine trial in the United States and Europe, in a manner that would infringe at least
16 claims 1, 2, 4, and 5 of the '221 Patent, if such combination occurred within the
17 United States.

18 54. Section 287 of Chapter 35 of the U.S.C. has been satisfied.

19 55. Defendants' infringing conduct will continue unless enjoined by this
20 Court.

21 56. Defendants' acts of direct infringement have been, and continue to be,
22 willful and deliberate and Defendants' acts of indirect infringement were, and
23 continue to be, knowing and intentional.

24 57. Allele is entitled to an award of damages adequate to compensate Allele
25 for patent infringement, as well as prejudgment interest from the date the
26 infringement began, but in no event less than a reasonable royalty as permitted by 35
27 U.S.C. § 284.

28

1 58. Allele is entitled to an award of treble damages for the period of any
2 willful infringement pursuant to 35 U.S.C. § 284.

3 59. Allele is entitled to a finding that this case is exceptional and an award
4 of interest, costs and attorneys' fees incurred by Allele in prosecuting this action as
5 provided by 35 U.S.C. § 285.

6 60. Allele is entitled to an award of pre-judgment and post-judgment interest
7 as provided by law.

8 61. Allele is entitled to such other and further relief as this Court or a jury
9 may deem just and proper.

10 **PRAYER FOR RELIEF**

11 WHEREFORE, in consideration of the foregoing, Allele respectfully prays
12 for a judgment against Defendants:

13 A. Finding that the '221 Patent has been infringed by Defendants in
14 violation of 35 U.S.C. §271;

15 B. Finding that Defendants' infringement of the '221 Patent is willful;

16 C. An award of damages adequate to compensate Allele for patent
17 infringement, as well as prejudgment interest from the date the infringement began,
18 but in no event less than a reasonable royalty as permitted by 35 U.S.C. § 284;

19 D. An award of treble damages for the period of any willful infringement
20 pursuant to 35 U.S.C. § 284;

21 E. A finding that this case is exceptional and an award of interest, costs
22 and attorneys' fees incurred by Allele in prosecuting this action as provided by 35
23 U.S.C. § 285;

24 F. For an award of pre-judgment and post-judgment interest as provided
25 by law; and

26 G. For such other and further relief as this Court or a jury may deem just
27 and proper.
28

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28

Dated: October 5, 2020

Respectfully Submitted,
TROUTMAN PEPPER HAMILTON
SANDERS LLP

/s/ Ben Lewis Wagner
Ben Lewis Wagner

Attorneys for Plaintiff
Allele Biotechnology and
Pharmaceuticals, Inc.

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28

DEMAND FOR JURY TRIAL

Plaintiff Allele Biotechnology and Pharmaceuticals, Inc. hereby demands a trial by the jury on its claims herein and all issues and claims so triable in this action.

Dated: October 5, 2020

Respectfully Submitted,

TROUTMAN PEPPER HAMILTON
SANDERS LLP

/s/ Ben Lewis Wagner
Ben Lewis Wagner

Attorneys for Plaintiff
Allele Biotechnology and
Pharmaceuticals, Inc.

TABLE OF EXHIBITS

Exhibit No.	Description	Page No.
1	'221 Patent	1
2	Assignment	23
3	Cell Host Article	27
4	“A high-throughput neutralizing antibody assay for COVID-19 diagnosis and vaccine evaluation,” Muruato, et al., bioRxiv preprint	39
5	SEC Form 6K	53
6	https://www.genengnews.com/news/pfizer-biontech-publish-encouraging-interim-phase-i-ii-data-for-covid-19-vaccine-construct/	82
7	Press Release: “Pfizer and BioNTech Granted FDA Fast Track Designation for Two Investigational mRNA-based Vaccine Candidates Against SARS-CoV2”	85
8	“RNA-Based COVID-19 Vaccine BNT162b2 Selected for a Pivotal Efficacy Study,” Walsh, et al. medRxiv preprint	90